title: The Nobori biolimus-eluting stent: update of available evidence.
abstract: Despite first-generation drug-eluting stents (DES) dramatically reduced the need for repeat revascularization in patients undergoing percutaneous coronary intervention, their use was associated with an increased risk of thrombotic events at long-term follow-up. The Nobori biolimus-eluting stent (BES) is a second-generation DES with a biodegradable poly-lactic acid polymer. During the last few years, several randomized trials have compared the Nobori BES with other DES, making this device the most investigated biodegradable DES. In this article, we reviewed current available data about Nobori BES from pharmacokinetic and observational studies to randomized clinical trials.
authors.affiliation: Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.
authors.forename: Raffaele
authors.initials: R
authors.lastname: Piccolo
authors.forename: Annamaria
authors.initials: A
authors.lastname: Nicolino
authors.forename: Gian Battista
authors.initials: GB
authors.lastname: Danzi
mesh_terms: D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D004337:Drug Carriers; D004353:Drug Evaluation, Preclinical; D054855:Drug-Eluting Stents; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D004337:Drug Carriers; C518022:umirolimus; D020123:Sirolimus